# An Observational Study, Called VERI-China, to Learn More About How Well Vericiguat Works and How Safe it is in Real-world Setting in People With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF) in China

> **NCT05728502** · — · COMPLETED · sponsor: **Bayer** · enrollment: 2400 (actual)

## Conditions studied

- Chronic Heart Failure With Reduced Ejection Fraction

## Interventions

- **DRUG:** Vericiguat (Verquvo, BAY1021189)
- **DRUG:** Standard of Care (SoC)

## Key facts

- **NCT ID:** NCT05728502
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2023-04-25
- **Primary completion:** 2025-10-29
- **Final completion:** 2025-12-26
- **Target enrollment:** 2400 (ACTUAL)
- **Last updated:** 2026-01-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05728502

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05728502, "An Observational Study, Called VERI-China, to Learn More About How Well Vericiguat Works and How Safe it is in Real-world Setting in People With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF) in China". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05728502. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*